SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value
5 references·1 citing·15 second hop
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value (2020)Interventional Pharmacoeconomics: A Novel…Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment (2019)Interventional Pharmacoeconom…Bringing down the cost of cancer treatment (2018)Bringing down the cost of can…A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer (2017)A Phamacoeconomic Analysis of…Overspending driven by oversized single dose vials of cancer drugs (2016)Overspending driven by oversi…Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011 (2015)Trends in the Cost and Use of…Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments (2021)Near-Equivalence: Generating …Male-Female Wage Differentials in Urban Labor Markets (1973)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries (2017)Rural-urban differences in financial burden among cancer survivors: an analysis of a nationally representative survey (2019)Understanding financial toxicity in head and neck cancer survivors (2019)Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force (2013)Indication-Specific Pricing for Cancer Drugs (2014)Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US (2020)Italian risk-sharing agreements on drugs: are they worthwhile? (2014)A global comparison of the cost of patented cancer drugs in relation to global differences in wealth (2017)Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund (2017)Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System (2018)Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis (2020)Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis (2024)
this work references cited by second hop

References

  • 2015Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011163 cited
  • 2016Overspending driven by oversized single dose vials of cancer drugs155 cited
  • 2017A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer106 cited
  • 2018Bringing down the cost of cancer treatment72 cited
  • 2019Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment56 cited

Cited by

  • 2021Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments54 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work